Cannabis Global Announces Breakthrough Discovery Enabling Potential for Development of Groundbreaking Infused Products in Emerging Cannabinol (CBN) Market
Los Angeles, CA – July 16, 2020 – Cannabis Global, Inc. (OTC PINK:MCTC) (“Cannabis Global” or the “Company”), a cannabinoid and hemp extract science-forward company developing infusion and delivery technologies, is excited to announce the successful application of production techniques developed for Tetrahydrocannabivarin (THC-V) to another rare cannabinoid, Cannabinol (CBN), which the Company believes may have enormous unexplored upside growth potential as a new cannabinoid-based products market.
This breakthrough discovery results from continued work on the Company’s “Project Varin” initiative, a core R&D effort launched in January 2020 to manufacture new nanotechnologies, infusions and consumer products based on rare cannabinoids, which has thus far yielded several important product development and production methodology breakthroughs that the Company now believes will enable more effective commercialization of products based on rare cannabinoids.
“Our research team has already proven our capability to produce high-quality polymeric nanoparticles and fibers of THC-V, but we also consider it important to be able to leverage our production techniques relative to other rare cannabinoids,” commented Arman Tabatabaei, CEO of Cannabis Global. “We are excited to report today the success of this effort, which comes in the form of the production of highly loaded nanofibers of CBN via our methods developed for THC-V. We believe this development allows Cannabis Global to more quickly expand our product portfolio as we continue to stake a claim in the rare cannabinoid sector, potentially unleashing underexploited growth potential in markets like CBN, with little or no real competition.”
The Company’s research team is nearing the completion of a subprogram of Project Varin designed to finalize high volume production methods. As part of this effort, manufactured CBN was successfully utilized, via the Company’s technologies, to produce highly loaded nanofibers. As an additional planned phase, the Company will seek to apply these established manufacturing protocols to other rare cannabinoids.
Mr. Tabatabaei continued, “Project Varin has exceeded our most optimistic expectations. Our next phase of CBN research will involve the design of new and innovative products based on rare cannabinoid CBN. We plan to continue programs under Project Varin throughout the second half of this year, while simultaneously launching our nature-based hemp infused products under the Hemp You Can Feel™ brand name. These will include our coffee products, alcohol replacement cocktail mixers, Hemp & Booch kombucha line and several other unique offerings, all based on the finest ingredients available.”
THC-V and CBN are not scheduled at the federal level. The Company’s THC-V products contain zero tetrahydrocannabinol (THC), far below the acceptable federal level of 0.3%, and zero heavy metals, pesticide and herbicide residues, nitrates and other impurities that are contained in most cannabis and hemp products. The Company’s products are not intended to diagnose, treat, cure or prevent any disease and are not for use by or sale to persons under the age of 18. The statements made regarding these products have not been evaluated by the Food and Drug Administration. The efficacy of these products has not been confirmed by FDA-approved research. These products are not intended to diagnose, treat, cure or prevent any disease. All information presented here is not meant as a substitute for or alternative to information from health care practitioners. Please consult your health care professional about potential interactions or other possible complications before using any product.
About Cannabis Global, Inc.
Cannabis Global, Inc. (OTC:MCTC) is a Nevada registered, fully reporting and audited publicly-traded company. With the hemp and cannabis industries moving very quickly and with a growing number of market entrants, Cannabis Global plans to concentrate its efforts on the middle portions of the hemp and cannabis value chain. The Company plans to actively pursue R&D programs and productization for exotic cannabinoid isolation, bioenhancement of cannabinoids and polymeric solid nanoparticles and nanofibers for addition into consumer products and for dermal application. The Company was reorganized during June of 2019 and announced its intent to enter the fast-growing cannabis sector. The Company is headed and managed by a group of highly experienced cannabis industry pioneers and entrepreneurs.
This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-k, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.
For more information, please contact:
Tiger Global Management
Source: Cannabis Global, Inc.